| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3b topline data readout example | Vafseo (vadadustat) anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months | Phase 3b | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | |
Phase 3b topline data readout example | Vafseo (vadadustat) anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months | Phase 3b | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | |
Phase 3b topline data readout example | Vafseo (vadadustat) anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months | Phase 3b | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
Akebia Therapeutics, Inc.
$0.9
-0.01 (-0.66%)
B 69Pipeline Score Undervalued Pharma · Commercial
Market Cap
249.56 M
EPS
-0.07
P/E Ratio
-
Value Trade
7.27 M
5.73 %
Week
-29.64 %
1 Month
-13.4 %
3 Month
-27.37 %
6 Month
-71.19 %
5 Year
-95.55 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
8.13 M
52 Week Range
0.81 - 3.22
% held by Insiders
2.8 %
% held by Institutions
40.59 %
Enterprise Value
168.39 M
Total Shares
277.19 M
Short %
7.12 %
Float Shares
264.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Akebia Therapeutics, Inc.
311Total events
9Upcoming
95Tier-1 (high impact)
2014 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Enrollment UpdatePraliciguatTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-11-06 | Vafseo® (vadadustat) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-11-06 | Vafseo® (vadadustat) | phase 3 data readout | Phase 3 | — | – | – | – |
2025-11-06 | Vafseo® (vadadustat) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B69
Pipeline Score $2.4B
Pipeline ValueUndervalued
Valuation Signal12
Drugs Scored9.4x
rNPV / MCap Top 95%
Micro Cap (rank 48 of 933)
Percentile RankAkebia Therapeutics, Inc. holds a solid B-grade pipeline (69/100), with $9.5B risk-adjusted pipeline value, led by ferric in End Stage Renal Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ferric Small molecule | Anemia of Chronic Kidney Disease | Phase 3 | NCT02268994 | 75% | $4.8B | COMPLETED | 234 | - | - | Jan 1, 2016 | - | Mar 22, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vadadustat | anemia due to chronic kidney disease | Phase 3 | 2026-05-04 | vadadustat demonstrated a statistically significant improvement relative to the erythropoiesis-stimulating agent (ESA), darbepoetin alfa, on a hierarchical composite endpoint of all-cause mortality and hospitalization Read More | Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology Read More | |
vadadustat | anemia due to chronic kidney disease | Phase 3 | 2026-05-04 | vadadustat demonstrated a statistically significant improvement relative to the erythropoiesis-stimulating agent (ESA), darbepoetin alfa, on a hierarchical composite endpoint of all-cause mortality and hospitalization Read More | Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology Read More | |
vadadustat | anemia due to chronic kidney disease | Phase 3 | 2026-05-04 | vadadustat demonstrated a statistically significant improvement relative to the erythropoiesis-stimulating agent (ESA), darbepoetin alfa, on a hierarchical composite endpoint of all-cause mortality and hospitalization Read More | Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AKBA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AKBA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AKBA▼ -26%on this news
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics reported strong financial results for Q2 2026, with Vafseo revenues reaching $21.3 million, a 34% increase from the previous quarter. The company also announced positive interim results from the VOICE trial, demonstrating improved safety for Vafseo compared to traditional therapies. Additionally, Akebia initiated a Phase 2 trial for ebribafusp, targeting rare kidney diseases, with initial data expected in 2027.
Read more →AKBAAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has launched a Phase 2 basket trial to assess ebribafusp, a next-generation complement inhibitor, for treating rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to evaluate the drug's safety, efficacy, and pharmacokinetics through weekly subcutaneous dosing. Initial data is expected in 2027.
Read more →AKBAAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics plans to release its financial results for Q2 2026 on August 5, 2026. The company will host a conference call at 4:30 p.m. EDT to discuss these results and recent business highlights. Investors can access the call via phone or a live webcast on Akebia's website.
Read more →AKBAU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
The interim analysis of the VOICE trial for Vafseo® revealed significant safety benefits for U.S. patients with anemia due to chronic kidney disease (CKD) on dialysis. The trial's primary investigator decided to halt the trial based on recommendations from the Independent Data Monitoring Committee and the Trial Steering Committee, highlighting the positive outcomes observed.
Read more →AKBA▼ -5.1%on this news
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics has announced the granting of a new patent for Vafseo (vadadustat), enhancing its intellectual property portfolio, which now includes 14 patents. The new patent extends the expiration of a composition of matter patent, reinforcing Akebia's competitive position in the dialysis market. Vafseo is currently the only oral HIF-PH inhibitor approved for treating anemia in chronic kidney disease patients on dialysis.
Read more →AKBA▼ -8.2%on this news
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Akebia Therapeutics granted stock options to a newly-hired employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options, totaling 8,400 shares, have an exercise price of $1.02 per share and will vest over four years. This move aims to enhance employee retention and align interests with the company's performance.
Read more →AKBAAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. Key executives Erik Ostrowski and Nicholas Grund will represent the company. A live webcast of the presentation will be available, along with a replay for 90 days. The conference runs from June 2-4, 2026, in New York.
Read more →AKBA▼ -20.3%on this news
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics reported strong financial results for the first quarter of 2026, with Vafseo® net product revenues reaching $15.8 million and a notable 60% increase in patients treated since the previous quarter. The company hosted a virtual R&D Day, showcasing ongoing clinical trials and promising developments in its kidney disease pipeline. Despite the revenue growth from Vafseo, Akebia experienced a decline in total revenues and reported a net loss, driven by fewer revenues from Auryxia. The company's cash resources are projected to support its operations for at least the next two years, reinforcing its position in the kidney disease market.
Read more →AKBA▲ +7.1%on this newsshared move
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Akebia Therapeutics announced the publication of a post-hoc analysis from its Phase 3 INNO2VATE program, demonstrating that vadadustat significantly reduces all-cause mortality and hospitalization in patients with anemia due to chronic kidney disease receiving dialysis. The findings, published in the Journal of the American Society of Nephrology, support the potential of vadadustat as a standard treatment. However, safety concerns remain, including risks of serious adverse events.
Read more →AKBA▲ +7.1%on this newsshared move
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. has granted stock options to seven newly-hired employees as part of an inducement to join the company. The inducement was made in compliance with Nasdaq Listing Rule 5635(c)(4) and involves options to purchase a total of 208,800 shares at an exercise price of $1.38 per share. The options will vest over four years, with an initial 25% vesting after one year, subject to continued employment with the company. Akebia aims to support individuals affected by kidney disease through its biopharmaceutical initiatives.
Read more →AKBAAkebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics has announced the scheduled release of its financial results for the first quarter of 2026, set for May 7, 2026. The release will precede a conference call at 8:00 a.m. EDT, where the company will discuss both its financial performance and recent business developments. Investors can access the call through a registration link, and a live webcast will also be available via the company's website. Akebia is focused on enhancing the lives of individuals affected by kidney disease.
Read more →AKBA▲ +5%on this news
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, a drug aimed at treating cardiac surgery-associated acute kidney injury. The trial will assess the drug's safety, tolerability, and pharmacokinetics. Akebia plans to report top-line data in early 2027, indicating a significant step forward in their kidney disease pipeline.
Read more →AKBAAkebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Akebia Therapeutics will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. CEO John P. Butler, CFO Erik Ostrowski, and CMO Dr. Steven Burke will participate in discussions about the company's commercial products and recent R&D developments. No formal presentations are scheduled for the event.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Akebia Therapeutics has granted stock options to 13 new employees as part of its hiring strategy. A total of 679,900 shares were offered at an exercise price of $1.39, which reflects the stock's closing price on the grant date. The options will vest over four years, promoting employee retention and aligning their interests with the company's performance.
Read more →AKBAAkebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
Akebia Therapeutics has appointed Philip J. Vickers, Ph.D., to its Board of Directors, effective April 1, 2026. Dr. Vickers, with extensive experience in biopharmaceutical leadership, will aid Akebia in advancing its programs for kidney and rare diseases. The company also announced the retirement of Steven C. Gilman, Ph.D., from the Board.
Read more →AKBAAkebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
Akebia Therapeutics will host a virtual R&D Day on April 2, 2026, featuring discussions on its kidney disease pipeline. Experts will review the current treatment landscape and Akebia's clinical programs. A live Q&A session will follow the presentations, allowing for direct interaction with the scientific community.
Read more →AKBAAkebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Akebia Therapeutics will present at the Leerink Partners 2026 Global Healthcare Conference. CEO John P. Butler and CFO Erik Ostrowski will participate in a Fireside Chat on March 9 at 8:00 AM ET. The conference runs from March 8-11, 2026, in Miami, and a webcast will be available on their website.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
Akebia Therapeutics has granted stock options to five new employees as part of their inducement program under Nasdaq Listing Rule 5635(c)(4). The options, totaling 46,200 shares, have an exercise price of $1.31 per share and will vest over four years. This move aims to enhance the company's workforce as it focuses on improving the lives of individuals affected by kidney disease.
Read more →AKBA▲ +9.1%on this newsshared move
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics reported a 49% increase in net product revenues for 2025, totaling $227.3 million. The company anticipates significant growth for its anemia treatment, Vafseo, in 2026, driven by expanded access and improved patient adherence. Additionally, Akebia is advancing its clinical pipeline with ongoing trials for praliciguat and plans for a rare kidney disease study.
Read more →AKBAAkebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its financial results for the fourth quarter and full year 2025 on February 26, 2026. The company plans to host a conference call at 8:00 a.m. EST to discuss these results and recent business highlights. Investors can access the call through registration and will be able to listen to a live webcast available on the company’s Investors website. Akebia, based in Cambridge, Massachusetts, focuses on addressing kidney disease.
Read more →AKBAAkebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Akebia Therapeutics announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. The executive team will engage in a Fireside Chat on February 12, 2026. The summit will occur in New York City, providing a prominent platform for discussing advancements in biotechnology.
Read more →AKBA▼ -7.9%on this news
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Akebia Therapeutics has provided a comprehensive update on its corporate progress and pipeline outlook for 2026. The company anticipates increased prescribing of its product, Vafseo, supported by a solid financial position and ongoing clinical trials for its rare kidney disease therapies. Notably, it has initiated Phase 2 studies for Praliciguat targeting focal segmental glomerulosclerosis and expects initial data from another trial in 2027. Additionally, potential risks regarding Vafseo's safety profile have been highlighted, emphasizing the need for cautious prescribing.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Akebia Therapeutics has granted stock options to a newly-hired employee as part of an inducement to join the company. The options, totaling 197,900 shares, have an exercise price of $1.61 and will vest over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and reflects Akebia's commitment to attracting talent.
Read more →AKBAAkebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Akebia Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial for praliciguat, targeting focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no approved treatments currently available. The trial will assess the drug's efficacy and safety in approximately 60 patients, employing a 24-week randomized, double-blind methodology. Following this, all participants will receive the treatment in an open-label phase. The company notes a promising safety profile for praliciguat based on previous clinical trials.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 1, 2025
Akebia Therapeutics has granted stock options to two newly-hired employees as an inducement for joining the company. The options, totaling 22,576 shares, were issued under Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.58 per share. These options will vest over four years, promoting employee retention.
Read more →AKBAAkebia Announces Establishment of Rare Kidney Disease Pipeline
Akebia Therapeutics has announced the establishment of a rare kidney disease pipeline, including the acquisition of AKB-097, a complement inhibitor, and the initiation of a Phase 2 trial for praliciguat in focal segmental glomerulosclerosis (FSGS). Both trials are set to commence in 2026, with expectations for significant advancements in treatment options for rare kidney diseases. The company aims to leverage its differentiated therapies to improve patient outcomes.
Read more →AKBAAkebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Akebia Therapeutics, a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease, is set to participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference. This event will occur on December 2, 2025, in New York City, where members of Akebia's executive team will speak. Interested parties can access a webcast of the presentation via the company's website following the conference.
Read more →AKBA▼ -18.1%on this news
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics reported strong financial results for Q3 2025, with Vafseo's net product revenues reaching $14.3 million. The company is making strides to establish Vafseo as the standard of care for anemia in dialysis patients, supported by favorable post-hoc data. However, Akebia faced setbacks with the FDA regarding its Phase 3 trial plans for non-dialysis patients.
Read more →AKBAVafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Akebia Therapeutics presented a post-hoc analysis from the Phase 3 INNO2VATE trials, indicating that vadadustat (Vafseo) significantly reduces the risk of all-cause mortality and hospitalization compared to darbepoetin alfa in dialysis-dependent patients. The findings were shared at the ASN Kidney Week 2025, highlighting the potential of vadadustat to become a standard treatment for anemia in chronic kidney disease. However, the treatment is associated with increased risks of thrombotic events.
Read more →AKBAAkebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics will present at two investor conferences in November 2025. CEO John P. Butler and CFO Erik Ostrowski will participate in fireside chats at the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London. Webcasts of the presentations will be available on their website.
Read more →AKBAAkebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced the upcoming release of its financial results for the third quarter of 2025, scheduled for November 10, 2025. The company will also conduct a conference call to discuss these results and recent business highlights, emphasizing its commitment to keeping investors informed. A live webcast of the conference call will be available on Akebia's website.
Read more →AKBA▼ -32%on this newsshared move
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Akebia Therapeutics announced it will not initiate the VALOR clinical trial for vadadustat to treat anemia in non-dialysis CKD patients after failing to reach an agreement with the FDA. The FDA indicated that a larger patient cohort would be necessary, increasing time and costs. Akebia remains focused on making Vafseo the standard of care for dialysis patients.
Read more →AKBA▲ +7.8%on this news
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Akebia Therapeutics announced its participation in ASN Kidney Week 2025, where it will present data on vadadustat, including a win odds analysis of mortality and hospitalization from the INNO2VATE trials. The event will showcase four posters detailing dosing recommendations and ongoing real-world studies. Vafseo, approved for CKD-related anemia in dialysis patients, is central to their presentations.
Read more →AKBAAkebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo (vadadustat) Across All IRC Dialysis Clinics
Akebia Therapeutics and Innovative Renal Care have announced that Vafseo (vadadustat) is now available nationwide across all IRC dialysis clinics. This development follows the FDA's approval of Vafseo for treating anemia due to chronic kidney disease in dialysis patients. By implementing a standardized treatment protocol, IRC aims to provide the therapy to over 55,000 patients and expand access significantly by late 2025. However, the treatment carries risks such as increased mortality and potential adverse cardiovascular effects that must be managed carefully.
Read more →AKBA▼ -20.5%on this news
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics reported financial results for Q2 2025, highlighting a significant increase in net product revenues driven by the launch of Vafseo. The drug's sales reached $13.3 million, with ongoing efforts to expand its use among dialysis patients. Upcoming clinical trials and collaborations, particularly with DaVita, aim to enhance patient access and gather vital efficacy data. While the financial outlook remains positive, the company faces challenges, including existing liabilities and the need for further studies to validate Vafseo's impact on patient quality of life.
Read more →AKBAAkebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Akebia Therapeutics, a biopharmaceutical company focusing on kidney disease, announced that its CEO, John P. Butler, will speak at Canaccord Genuity's 45th Annual Growth Conference on August 13, 2025. The event is scheduled to occur from August 12-14 in Boston. Interested parties can access a webcast of the presentation via the company's website following the conference. This participation emphasizes Akebia's dedication to improving the lives of individuals affected by kidney disease.
Read more →AKBAAkebia Initiates Vafseo (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Akebia Therapeutics has launched a post-marketing study for its anemia treatment, Vafseo (vadadustat), targeting patients with chronic kidney disease undergoing dialysis. The study, named the VOCAL trial, will analyze the safety and efficacy of a three-times-per-week dosing regimen as compared to standard treatments. Conducted within DaVita dialysis clinics, the trial aims to enroll around 350 patients, assessing key changes in hemoglobin and treatment-related adverse events over a 33-week period. With Vafseo having been approved in early 2024, this initiative seeks to expand its clinical benefits in real-world applications.
Read more →AKBAAkebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. plans to announce its financial results for the second quarter of 2025 on August 7, 2025. A conference call will follow to discuss these results and recent business highlights. The company, based in Cambridge, Massachusetts, emphasizes its mission to enhance the lives of patients dealing with kidney disease. Interested parties can register for the call via a provided link or watch it live on Akebia's website.
Read more →AKBAAkebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that its Chief Commercial Officer, Nik Grund, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference. The event is scheduled for July 14, 2025, at 10:00 AM EDT. A webcast of the presentation will be available on Akebia's website, offering insights into the company's developments in addressing kidney disease.
Read more →AKBAAkebia Therapeutics, Inc. 2023 STOCK INCENTIVE PLAN (as amended by Amendment No. 1) 1. Purpose The purpose of this 2023 Stock Incentive Plan (the " Plan ") of Akebia Therapeutics, Inc., a Delaware corporation (the " Comp
Akebia Therapeutics, Inc. has introduced an amended 2023 Stock Incentive Plan to enhance its ability to attract, retain, and motivate key contributors. The plan includes a range of awards such as stock options and performance-based incentives. It aims to align the interests of employees with those of stockholders by providing equity ownership opportunities. The Board will oversee the administration of the plan, which is open to employees, officers, directors, and selected consultants.
Read more →AKBAAkebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
Akebia Therapeutics announced that its Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on June 5, 2025. This conference, held in New York City from June 3-5, aims to bring together various stakeholders in the healthcare sector. A webcast of the presentation will be available on Akebia's website. The company focuses on improving the lives of people impacted by kidney disease.
Read more →AKBAAkebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
Akebia Therapeutics has announced its participation in the 62nd European Renal Association Congress scheduled for June 4-7, 2025. The company will present three key studies focusing on treatments for chronic kidney disease, including data on cardiovascular safety and inflammation-induced anemia. This event marks a significant opportunity for Akebia to highlight its ongoing research efforts in improving patient care for kidney disease. Additionally, the presentations will be available both virtually and in-person in Vienna.
Read more →AKBAAkebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Akebia Therapeutics, Inc. announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for May 20, 2025. John Butler, the CEO, and Nik Grund, the CCO, will partake in a Fireside Chat at the event. The conference aims to enhance investor engagement and communication about the company's initiatives in the kidney disease sector.
Read more →AKBA▲ +6.5%on this newsshared move
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics reported a strong financial performance for the first quarter of 2025, driven by the successful launch of its anemia treatment, Vafseo (vadadustat), which generated $12 million in net product revenues. The company achieved total net product revenues of $55.8 million, reflecting significant growth from the previous year. Akebia also bolstered its balance sheet with a $50 million public offering and reported positive early engagement from the dialysis community regarding Vafseo prescriptions. However, the loss of market exclusivity for Auryxia and associated liabilities present ongoing challenges.
Read more →AKBAAkebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. will release its financial results for the first quarter of 2025 on May 8, 2025. The company will host a conference call at 8:00 a.m. EDT the same day, where it will discuss both the financial results and recent business highlights. Interested parties can register for the call or access a live webcast through the company's website. Akebia, based in Cambridge, Massachusetts, aims to improve the lives of individuals affected by kidney disease.
Read more →AKBAAkebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL , an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
Akebia Therapeutics has announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding XOANACYL, an oral therapy for chronic kidney disease. The recommendation advises the European Commission to approve the drug, which addresses elevated serum phosphorous and iron deficiency in CKD patients. Akebia has licensed the rights to develop and commercialize the drug to Averoa, which will further the treatment's availability in Europe. A final decision from the European Commission is expected in about two months.
Read more →AKBAAkebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
Akebia Therapeutics, Inc. will showcase its latest research findings at the National Kidney Foundation Spring Clinical Meetings 2025 in Boston from April 10-13. The company will present two posters, including studies on the cardiovascular risks associated with its treatment Vadadustat. Additionally, Dr. Wolfgang Winkelmayer will provide insights into the treatment's efficacy in different age groups of patients with dialysis-dependent chronic kidney disease during an oral presentation. Akebia aims to highlight its dedication to improving the lives of those affected by kidney disease.
Read more →AKBA▲ +11.4%on this news
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Akebia Therapeutics has announced the pricing of its public offering of 25 million shares of common stock at $2.00 per share, aimed at raising $50 million in gross proceeds. The offering is set to close on March 21, 2025, pending customary conditions. The company has also granted underwriters a 30-day option to purchase an additional 3.75 million shares. Akebia emphasizes its mission to benefit those with kidney disease, though it also acknowledges the inherent risks in such financial offerings.
Read more →AKBA▲ +11.4%on this news
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
Akebia Therapeutics has announced a proposed underwritten public offering of common stock to raise capital, with all shares offered by the company itself. The offering is contingent on market and other conditions, and there are uncertainties regarding its completion, size, and terms. Established firms Leerink Partners and Piper Sandler & Co. are managing the offering. This action reflects Akebia's ongoing efforts to support its operations and developments in the kidney disease sector.
Read more →AKBA▼ -12.4%on this news· ran to +32% by day 3
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo (vadadustat) Commercial Launch Progress Update
Akebia Therapeutics announced its fourth quarter and full year 2024 financial results, highlighting strong early sales of its newly launched anemia treatment, Vafseo. The company expects Vafseo to generate approximately $10-$11 million in net product revenue during the first quarter of 2025. Akebia is optimistic about expanding Vafseo’s label to treat non-dialysis chronic kidney disease populations and plans to initiate the Phase 3 VALOR study this year. However, the company reported an increased net loss for the year, reflecting challenges in revenue generation amid rising operational costs.
Read more →AKBAAkebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. announced it will release its financial results for Q4 and full-year 2024 on March 13, 2025. The company will hold a conference call the same day to discuss these results and provide insights into recent business developments. Investors can attend the call via registration and access a live webcast on Akebia's website. This event highlights the company's commitment to transparency and communication with stakeholders.
Read more →AKBA▲ +6.9%on this news
Akebia Therapeutics Announces Multiple Positive Business Updates Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has announced significant updates regarding its product Vafseo, which is now available for nearly all dialysis patients in the U.S. The company has secured commercial supply contracts and plans to initiate a Phase 3 trial for treating anemia in non-dialysis chronic kidney disease patients by mid-2025. Akebia's CEO expressed optimism about Vafseo becoming a new standard of care.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has granted stock options to a newly-hired employee as an inducement for joining the company. The options, totaling 3,000 shares, have an exercise price of $1.90 per share, matching the stock's closing price on the grant date. These options will vest over four years, reflecting Akebia's strategy to retain talent in the biopharmaceutical sector.
Read more →AKBA▼ -5.9%on this news
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics announced that CEO John Butler will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2024. During the presentation, he will provide updates on the company's initiatives, including the U.S. launch of Vafseo (vadadustat). The conference is scheduled for January 13-16, 2025, in San Francisco.
Read more →AKBAU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has initiated the VOICE trial, enrolling the first patients for Vafseo (vadadustat), aimed at treating anemia in chronic kidney disease (CKD) patients on dialysis. The trial will assess Vafseo's safety and efficacy compared to standard care, with results expected in approximately 18 months. Vafseo is set to launch in January 2025 following FDA approval.
Read more →AKBAAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics will present at the 36th Annual Piper Sandler Healthcare Conference on December 3, 2024. CEO John Butler will participate in a Fireside Discussion during the event. The conference will be held in New York from December 3-5, and a webcast of the presentation will be available on Akebia's website for six months.
Read more →AKBAVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics announced the publication of the FO 2 CUS trial results in the American Journal of Kidney Disease, highlighting the efficacy and safety of vadadustat for hemodialysis patients. The FDA approved Vafseo, the oral formulation of vadadustat, for treating anemia due to chronic kidney disease in patients receiving dialysis. The publication marks a significant milestone in Akebia's research efforts.
Read more →AKBAAkebia Therapeutics to Present at the Jefferies London Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics, Inc. will present at the Jefferies London Healthcare Conference on November 21, 2024. CEO John Butler is scheduled to speak at 1:00 PM GMT. The conference runs from November 19-21, 2024, in London, and a webcast of the presentation will be available for 30 days on Akebia's website.
Read more →AKBA▼ -6.7%on this newsshared move
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics reported its Q3 2024 financial results, highlighting the upcoming U.S. launch of Vafseo (vadadustat) expected in January 2025. The company has secured coverage for Vafseo for over 300,000 dialysis patients and received TDAPA reimbursement approval. Despite a net loss of $20 million, Akebia continues to prepare for a strong market entry and has engaged in collaborative trials to support Vafseo's clinical evidence.
Read more →AKBAAkebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on...
Akebia Therapeutics plans to announce its third quarter financial results on November 7, 2024. The company will host a conference call at 8:00 a.m. EST to discuss these results along with recent business highlights. Investors can access the call via registration and a live webcast will also be available on their website.
Read more →AKBA▲ +19.7%on this news
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has entered a multi-year commercial supply contract with a leading kidney care provider, enhancing access to Vafseo (vadadustat) for dialysis patients. The FDA approved Vafseo for treating anemia due to chronic kidney disease in adults on dialysis, and it will be available in the U.S. starting January 2025. The contract aims to provide a new option for anemia management in over 200,000 patients.
Read more →AKBAAkebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics will present seven posters at ASN Kidney Week 2024, focusing on clinical data for vadadustat, an oral HIF-PH inhibitor. The presentations will cover various aspects of vadadustat's efficacy and safety, particularly in patients with chronic kidney disease. The company anticipates U.S. market availability for vadadustat in January 2025.
Read more →AKBACMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics announced that CMS has approved TDAPA reimbursement for Vafseo (vadadustat), effective January 1, 2025. This reimbursement will support dialysis organizations in managing anemia for patients receiving dialysis. Vafseo, approved by the FDA in March 2024, is expected to enhance treatment options for chronic kidney disease patients. However, the drug carries significant risks, including increased mortality and thrombotic events.
Read more →AKBAAkebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and ...
Akebia Therapeutics has entered a multi-year commercial supply contract with U.S. Renal Care to provide Vafseo for dialysis patients. The agreement allows USRC physicians to prescribe Vafseo, which was approved by the FDA for treating anemia due to chronic kidney disease in adults on dialysis. The drug is expected to be available in January 2025.
Read more →AKBAAkebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and ...
Akebia Therapeutics and U.S. Renal Care have announced the initiation of the VOICE trial to evaluate the efficacy of Vafseo (vadadustat) in dialysis patients. The trial aims to enroll around 2,200 patients to compare Vafseo with standard care, focusing on mortality and hospitalization rates. This collaboration seeks to build real-world evidence on Vafseo's potential benefits and risks in treating anemia due to chronic kidney disease.
Read more →AKBA▲ +7.2%on this news· ran to +21% by day 3
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics reported its financial results for Q2 2024, highlighting significant progress in the launch of Vafseo, which is set for market availability in January 2025. The company has completed its TDAPA application and announced pricing for Vafseo. Despite a decrease in total revenues, Auryxia's product revenues remain stable, and Akebia's cash resources are expected to support operations for at least two years.
Read more →AKBAAkebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on...
Akebia Therapeutics will release its financial results for Q2 2024 on August 8, 2024, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET to discuss the results and recent business highlights. The call can be accessed via phone or through a live webcast on Akebia's website.
Read more →AKBAAkebia Therapeutics to Present at Upcoming Investor Conferences Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has announced its participation in two upcoming investor conferences in August 2024. The CEO, John Butler, will participate in a fireside chat at the BTIG virtual Biotechnology Conference and present at the Canaccord Genuity Annual Growth Conference. Webcast access will be available for interested investors.
Read more →AKBA▲ +17.6%on this news· ran to +31% by day 3
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has regained full rights to sell Vafseo (vadadustat) Tablets in the U.S. after terminating a royalty agreement with CSL Vifor. The company has set the wholesale acquisition cost for Vafseo at $1,278 for a 30-day supply and submitted a TDAPA application, expecting designation by January 2025. An investor conference call is scheduled for July 11, 2024.
Read more →AKBA▲ +7%on this news
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics announced that CEO John Butler will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024. The presentation will focus on updates regarding the commercial launch of Vafseo (vadadustat) Tablets. A webcast of the presentation will be available for 30 days on Akebia's website.
Read more →AKBAAkebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has appointed Erik Ostrowski as Chief Financial Officer and Chief Business Officer. Ostrowski, an experienced biotech executive, is expected to enhance Akebia's leadership team during a critical phase, particularly with the launch of Vafseo. His background includes significant roles in corporate finance and strategic transactions, positioning Akebia for future growth.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has granted stock options to four new employees as part of their inducement program under Nasdaq Listing Rule 5635(c)(4). A total of 76,000 shares are involved, with an exercise price set at $1.12 per share. The options will vest over four years, promoting employee retention and aligning interests with the company's performance.
Read more →AKBAAkebia Therapeutics to Present at the Jefferies Global Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that CEO John Butler will present at the Jefferies Global Healthcare Conference on June 5, 2024. The conference will be held in New York from June 4-6, 2024. A webcast of the presentation will be available for 30 days on Akebia's website.
Read more →AKBAAkebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics announced that CEO John Butler will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on May 20, 2024. The event will take place in New York, and a webcast of the presentation will be available for 30 days on the company's website. This engagement underscores Akebia's focus on improving the lives of those affected by kidney disease.
Read more →AKBAAkebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics reported its financial results for Q1 2024, highlighting the FDA approval of Vafseo for anemia due to chronic kidney disease. The company anticipates launching Vafseo in January 2025 and expects growth in Auryxia revenues. Despite a decrease in total revenues and a net loss, Akebia maintains a strong cash position to support its operations.
Read more →AKBAAkebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on...
Akebia Therapeutics plans to release its financial results for Q1 2024 on May 9, 2024. The company will host a conference call at 8:00 a.m. ET to discuss these results and recent business highlights. Investors can access the call via phone or through a live webcast on Akebia's website.
Read more →AKBA▲ +12%on this news
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has received FDA approval for Vafseo (vadadustat) tablets, aimed at treating anemia due to chronic kidney disease in adults on dialysis. This once-daily oral medication activates the body's response to hypoxia, stimulating erythropoietin production. The approval is based on extensive clinical data and aims to provide an alternative to injectable treatments currently used. Akebia plans to leverage its commercial team and partnerships for a successful launch.
Read more →AKBAAkebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics reported its financial results for Q4 and full year 2023, highlighting a potential U.S. approval for vadadustat on March 27, 2024. The company strengthened its balance sheet with a $55 million loan and $26 million from stock sales. Despite a decrease in total revenues, Akebia aims for growth in Auryxia sales and is preparing for vadadustat's launch if approved.
Read more →AKBAAkebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics plans to report its fourth quarter and full year 2023 financial results on March 14, 2024. The company will not hold a conference call due to the upcoming PDUFA target action date for vadadustat, which is under FDA review for treating anemia in chronic kidney disease patients on dialysis. Akebia aims to enhance the lives of those affected by kidney disease.
Read more →AKBA▼ -8.4%on this news
Akebia Secures $55 Million Term Loan Financing Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has closed a $55 million loan facility with BlackRock, enhancing its financial stability as it approaches a critical FDA decision on vadadustat. The first tranche of $37 million has been drawn to pay down previous debts, extending the interest-only period until late 2025. This financing aims to support Akebia's strategic initiatives leading up to the potential launch of vadadustat for patients with anemia.
Read more →AKBAAkebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics has appointed Nicholas Grund as Chief Commercial Officer, aiming to enhance its commercial strategy in the renal market. Grund brings significant experience from previous roles in the pharmaceutical industry, which will be vital as the company prepares for the potential U.S. launch of vadadustat. The leadership change is expected to bolster Akebia's efforts to maximize revenue from its products, including Auryxia.
Read more →AKBA▲ +6.1%on this newsshared move
presentation Unlocking the Power of the Hypoxia- Inducible Factor (HIF) Pathway Delivering Innovation for Patients with Chronic Kidney Disease (CKD) January 2024 Nasdaq: AKBA 1 Statements in this presentation regarding A
Akebia Therapeutics is focusing on its hypoxia-inducible factor (HIF) pathway to enhance treatments for patients with chronic kidney disease (CKD). The company forecasts preliminary revenue growth for its product Auryxia in 2024 and is preparing for a critical FDA decision on its new drug application for vadadustat. If approved, vadadustat is expected to offer new options for anemia management in dialysis patients. However, Akebia faces risks including regulatory uncertainties, competitive pressures, and challenges in maintaining operational stability as it aims for profitability.
Read more →AKBAAkebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics, Inc. announced that CEO John Butler will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The conference will be held in San Francisco from January 8 to 11, 2024. A webcast of the presentation will be available on Akebia's website for 30 days post-conference.
Read more →AKBA▼ -6.7%on this news
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Akebia Therapeutics has announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for vadadustat, intended for the treatment of anemia due to chronic kidney disease. This acceptance initiates a six-month review period, culminating in a user fee goal date set for March 27, 2024. The resubmission addresses previous issues raised by the FDA and includes substantial safety data from Japan, where vadadustat is currently approved. Akebia aims to prepare for a commercial launch of the drug in the U.S. during the second half of 2024, contingent upon approval.
Read more →AKBAAkebia Announces Approval of Vafseo (vadadustat) in Australia and Provides Commercial Update
Akebia Therapeutics announced the approval of Vafseo (vadadustat) in Australia for treating anemia associated with chronic kidney disease in dialysis patients. The approval is supported by data from over 7,500 patients, demonstrating that vadadustat met both efficacy and safety endpoints in its clinical trials. Additionally, Akebia is expanding its commercial team in preparation for a potential U.S. launch of vadadustat. However, the company has adjusted its revenue expectations for Auryxia downward due to current market conditions.
Read more →AKBA▼ -8%on this news
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on
Akebia Therapeutics reported its financial results for Q2 2023, revealing a total revenue of $56.4 million, a significant decline from $126.4 million in the same quarter a year prior. The company plans to resubmit its NDA for vadadustat, aimed at treating anemia due to CKD, by the end of Q3 2023, projecting a potential PDUFA date in March 2024. Akebia reaffirmed its revenue guidance for Auryxia, demonstrating resilience in its product performance despite overall financial losses.
Read more →AKBAAkebia Therapeutics to Report Second Quarter Financial Results by
Akebia Therapeutics has announced that it will report its second quarter financial results by August 25, 2023. The announcement comes after the company filed a Form 12b-25 Notification of Late Filing due to non-compliance with Nasdaq listing rules regarding timely financial reports. Although this situation puts Akebia at risk of delisting, the Nasdaq notice does not have any immediate effect on the company's stock listing. Akebia anticipates regaining compliance following the timely filing of its Form 10-Q.
Read more →AKBA▼ -14.3%on this news
Akebia Therapeutics Provides Update on Form 10-Q Filing Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes
Akebia Therapeutics announced a late filing of its form 10-Q for Q2 2023 due to identified accounting errors related to Auryxia reporting. Despite this setback, the company affirms its revenue guidance of $175 to $180 million for the year and expresses confidence in its financial resources to sustain operations through at least the next twelve months. Additionally, Akebia is preparing to resubmit its New Drug Application for vadadustat by the end of Q3 2023, believing that the filing delay will not affect its services to patients.
Read more →AKBAAkebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
Akebia is preparing to resubmit its NDA for vadadustat, an anemia treatment for dialysis patients, following a recent FDA meeting. Meanwhile, GSK's Jesduvroq has received FDA approval but faces concerns regarding its serious side effects and lack of market enthusiasm among physicians. As Akebia's competition in the CKD anemia space heats up with other products like FibroGen's Evrenzo and GSK's daprodustat, nephrologists in the EU appear willing to integrate multiple similar therapies into their practice. The renal anemia treatment landscape is anticipating changes as various approvals move forward or face delays.
Read more →AKBADocument Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
Akebia Therapeutics announced the completion of a Type A meeting with the FDA to discuss the resubmission of its New Drug Application (NDA) for vadadustat, intended for treating anemia due to chronic kidney disease (CKD) in dialysis patients. The meeting was described as informative and productive, paving the way for the company to align on the NDA resubmission process. Akebia plans to submit the NDA by the end of the third quarter of 2023 and anticipates receiving FDA feedback by mid-August.
Read more →AKBA▲ +6.7%on this news
Statements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward- looking statements within the meaning of the U.S. Pr
Akebia Therapeutics, Inc. recently announced its plans to resubmit its NDA for vadadustat and move forward with commercializing Vafseo in Europe following its approval in the EU and UK. The FDA has provided guidance on the resubmission without requiring new clinical data, which is a positive development for the company. However, there are lingering concerns regarding previous clinical trial risks and market acceptance. Akebia anticipates launching Vafseo in early 2025 if approved, and it is well positioned to maximize the product's value based on its existing commercial organization.
Read more →AKBA▼ -15.2%on this news
FDA Provides Akebia Therapeutics a Path Forward for Vadadustat FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request
Akebia Therapeutics received feedback from the FDA regarding its vadadustat NDA resubmission. Although the FDA denied the formal dispute resolution request, it provided guidance on resubmitting without the requirement for additional clinical data. Concerns about thromboembolic events and drug-induced liver injury were noted, but the FDA indicated that these risks could be manageable. Akebia plans to submit the NDA in the second half of 2023, leveraging data from its commercial experience in Japan.
Read more →AKBA▼ -15.4%on this news· ran to -27% by day 3shared move
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel P tter GmbH Co.KG for the Commercialization of Vafseo for the Treatment of Anemia associated with CKD in Europe and Australia Medice brings exten
Akebia Therapeutics has entered into a licensing agreement with Medice Arzneimittel P tter GmbH Co.KG to commercialize Vafseo, a treatment for anemia linked to chronic kidney disease (CKD), across Europe and Australia. Akebia will receive an upfront payment of $10 million, alongside potential commercial milestones that could reach $100 million and tiered royalties of up to 30% of net sales. This collaboration is expected to leverage Medice's extensive experience in nephrology and dialysis care. Akebia retains development rights for additional indications of Vafseo not linked to dialysis, indicating a strategic move to maximize its product’s market potential.
Read more →AKBA▲ +21.6%on this newsshared move
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Akebia Therapeutics has announced that it has regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share. This follows a previous notice from Nasdaq indicating that the company was at risk of delisting. After filing an appeal and securing a hearing, the company can now continue trading on the Nasdaq Capital Market, allowing it to maintain its listing status.
Read more →AKBAAkebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Akebia to host conference call on May 8 at 8:30 a.m. ET Announced vadadustat is now approved in 32 countries following Europ
Akebia Therapeutics reported its first quarter 2023 financial results, highlighting the approval of vadadustat in 32 countries and positive study results. The company aims to complete a partnership for the drug's launch in Europe while navigating an ongoing appeal process with the FDA. Financial figures disclosed a significant reduction in operating costs, although revenue fluctuations were noted due to inventory challenges. A conference call is scheduled for May 8 to discuss these developments in further detail.
Read more →AKBA▼ -22.3%on this news· ran to -34% by day 3
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights Akebia to host conference call on March 9 at 8:30 a.m. ET Receives positive CHMP opinion for Vafseo (vadadust
Akebia Therapeutics announced its financial results for Q4 and full year 2022, highlighting a strategic focus on maximizing Auryxia revenue and supporting vadadustat globally. The company received a positive opinion from the CHMP for Vafseo, anticipating potential marketing authorization in May 2023. Akebia reported a nearly 25% increase in net product revenue for Auryxia over the previous year, though it remains cautious about the phosphate binder market recovery due to ongoing challenges. The company is actively seeking a partner for Vafseo's commercialization in Europe, should it receive approval.
Read more →AKBA▼ -25.5%on this news
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Akebia Therapeutics has received a second interim response from the FDA regarding its appeal for vadadustat, intended for treating anemia in chronic kidney disease patients. The appeal is now overseen by Dr. Peter Stein, who will consult with various experts before making a decision. Akebia expects to hear back within thirty days of these consultations. The drug remains under review in Europe, while it has been approved for use in Japan.
Read more →AKBAStatements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Pri
Akebia Therapeutics has provided a detailed presentation on its strategic plans and financial outlook, highlighting its focus on vadadustat and Auryxia. The company anticipates a Formal Dispute Resolution Request response from the FDA regarding vadadustat. Financially, Auryxia's revenue has increased significantly, while cost management efforts show a commitment to improving financial health. However, regulatory approval risks and uncertainties regarding product effectiveness remain a concern for the company moving forward.
Read more →AKBA▲ +7.3%on this news
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on November 3 at 4:30 p.m. ET Filed Formal Dispute Resolution Request related to the CRL for
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on November 3 at 4:30 p.m. ET CAMBRIDGE, Mass. November 3, 2022 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpos
Read more →AKBAAkebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on August 4 at 4:30 p.m. ET Reported net Auryxia (ferric citrate) product revenue of $43.7M,
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Akebia to host conference call on August 4 at 4:30 p.m. ET CAMBRIDGE, Mass. August 4, 2022 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose t
Read more →AKBA▲ +23.9%on this news
AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or a
Read more →AKBA▼ -10.3%on this newsshared move
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update Net Auryxia (ferric citrate) product revenue of $41.4M, a 36% increase over Q1 2021 2022 Net Auryxia product revenue guidance of $165 $
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update CAMBRIDGE, Mass. May 9, 2022 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced fi
Read more →AKBA▼ -66%on this newsshared move
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Company to host conference call on Wednesday
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Company to host conference call on Wednesday, March 30, 2022 at 6:00 p.m. CAMBRIDGE, Mass. March 30, 2022 Akebia Therap
Read more →AKBA▲ +6%on this news
AKEBIA THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Akebia Therapeutics, Inc.
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA) in the United States District Court for the
Read more →AKBAAkebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights Akebia is launch-ready pending FDA decision for vadadustat on PDUFA date
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business CAMBRIDGE, Mass. March 1, 2022 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Read more →AKBA▲ +8.8%on this news· ran to +21% by day 3
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch Agreement Leverages Vifor Pharma s Exclusive Distribution Arrangement with Certain Dialysis Or
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch Agreement Leverages Vifor Pharma s Exclusive Distribution Arrangement with Certain Dialysis Organizations Agreement Defines Profit Share Economics of Po
Read more →AKBA▼ -9%on this news
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones Pre-commercialization activities underway in anticipation of
Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted b
Read more →AKBACAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Statements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning o
BETTERING THE LIVES OF PEOPLE IMPACTED BY KIDNEY DISEASE John P. Butler, President and CEO (Nasdaq: AKBA) September 2021 Exhibit 99.1 FORWARD-LOOKING STATEMENTS Statements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions and
Read more →AKBA▲ +15.7%on this news
Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones Vadadustat New Drug Application (NDA) Accepted for Filing with the U.S. Food and Drug Administration (FDA) Vadadu
Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones CAMBRIDGE, Mass. Aug. 5, 2021 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney d
Read more →AKBAAkebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis Vadadustat assigned
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis CAMBRIDGE, Mass. and Tokyo, Japan June 1, 2021 Akebia Therapeutics, Inc. (Nas
Read more →AKBAAkebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) Results of global Phase 3 progra
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones CAMBRIDGE, Mass. May 10, 2021 Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today
Read more →AKBAAkebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis CAMBRIDGE, Mass., March 30, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
Read more →AKBAAkebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates Full-year 2020 net product revenue increases to $128.9 million, up 16% from 2019 Company on track to submit vadadustat NDA
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides CAMBRIDGE, Mass. February 25, 2021 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported
Read more →AKBAStatements in this presentation regarding Akebia's strategy, plans, prospects, populations; the timing of or likelihood of regulatory filings and approvals, including labeling or expectations, beliefs, intentions and goa
Statements in this presentation regarding Akebia's strategy, plans, prospects, populations; the timing of or likelihood of regulatory filings and approvals, including labeling or expectations, beliefs, intentions and goals are forward-looking statements within the meaning of oth
Read more →AKBAAkebia Reports Third Quarter 2020 Financial Results and Recent Business Updates Presented positive global Phase 3 data for vadadustat from the INNO 2 VATE program for the treatment of anemia due to chronic kidney disease
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates CAMBRIDGE, Mass. November 5, 2020 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported f
Read more →AKBAAkebia Therapeutics Announces Top-Line Results from its PRO 2 TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis PRO 2 TECT achieves primary
Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Adult Patients Not on Dialysis CAMBRIDGE, Mass. September 3, 2020 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
Read more →AKBAAkebia Reports Second Quarter 2020 Financial Results Top-line data readout of global Phase 3 PRO 2 TECT program of vadadustat for treatment of anemia due to CKD in adult patients not on dialysis on track for early Septem
Akebia Reports Second Quarter 2020 Financial Results CAMBRIDGE, Mass. August 10, 2020 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the sec
Read more →AKBAAkebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results Vadad
Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results CAMBRIDGE, Mass. May 5, 2020 Akebia Therapeutics, Inc. (Nasd
Read more →AKBAAkebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights Top-line data readouts of global Phase 3 program for vadadustat on track for
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights CAMBRIDGE, Mass. March 10, 2020 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and
Read more →AKBAAkebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results Funding expected to extend Company s cash runway into 2021, well past its expected topline data readouts for glob
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results CAMBRIDGE, Mass. (BUSINESS WIRE) Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics fo
Read more →AKBAAkebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights Auryxia Revenue Increases to $29.1 Million for Q2 FY19, Up 21% from Q2 FY18 and Up 26% fro
Akebia Therapeutics Reports Second Quarter 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights CAMBRIDGE, Mass. August 8, 2019 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercializat
Read more →AKBAAkebia Therapeutics DEDICATED TO ADVANCING CARE FOR PATIENTS WITH KIDNEY DISEASE CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Statements in this presentation regarding Akebia s strategy, plans, prospects, required to
Akebia Therapeutics DEDICATED TO ADVANCING CARE FOR PATIENTS WITH KIDNEY DISEASE CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Statements in this presentation regarding Akebia s strategy, plans, prospects, required to develop and commercialize Akebia s product candidates and
Read more →AKBAAkebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO 2 VATE Studies and Announces Key Executive Appointments Net Product Revenue for Auryxia Increases to $23.1 Milli
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments CAMBRIDGE, Mass.--May 9, 2019 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the
Read more →AKBAAkebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance First regulatory submissi
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights Substantial revenue growth opportunity for Auryxia following robust 2018 commercial performance First regulatory submission for vadadustat expected in 2019 in Japan, following pos
Read more →AKBAStatements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions or goals are forward-looking statements within the meaning of the Private Securities Litigation Reform Act
January 2019 Exhibit 99.1 Statements in this presentation regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions or goals are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including b
Read more →AKBAVOTING AGREEMENT THIS VOTING AGREEMENT (this Agreement ) is made and entered into as of
VOTING AGREEMENT (this Agreement ) is made and entered into as of June 28, 2018, by and between Akebia Therapeutics, Inc., a Delaware corporation ( Akebia ), and the undersigned stockholder (the Stockholder ) of Keryx Biopharmaceuticals, Inc., a Delaware corporation ( Keryx ).
Read more →AKBAAkebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan | Akebia Therapeutics
Akebia Therapeutics announced that Japan Tobacco Inc. received approval from the PMDA for an additional indication of Riona® to treat iron deficiency anemia in adult patients in Japan, expanding its use beyond chronic kidney disease.
Read more →AKBAAkebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer
Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer CAMBRIDGE, Mass. May 25, 2017 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-induci
Read more →AKBAAkebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Use in its Dialysis Facilities an
Read more →AKBAAkebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Maximizes Efficiency of Global Development and Commercialization Committed Capital a
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Maximizes Efficiency of Global Development and Commercialization Committed Capital and Potential Milestone Payments from Otsuka of up to $865
Read more →AKBAAkebia Therapeutics Appoints Scott A. Canute to its Board of Directors
Akebia Therapeutics Appoints Scott A. Canute to its Board of Directors CAMBRIDGE, Mass. August 2, 2016 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat
Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat CAMBRIDGE, Mass. March 9, 2016 - Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through
Read more →AKBAAkebia Initiates Phase 3 PRO 2 TECT Program -Achieved All Corporate Objectives for 2015- CAMBRIDGE, MA
Akebia Initiates Phase 3 PRO2TECT Program -Achieved All Corporate Objectives for 2015- CAMBRIDGE, MA, January 4, 2016 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the bio
Read more →AKBAAkebia Announces Third Quarter 2015 Financial Results
-Positive Phase 2 data of vadadustat in Dialysis Dependent Chronic Kidney Disease (CKD) Patients Presented at American Society of Nephrology (ASN) Kidney Week- -On Track to Initiate Phase 3 PRO2TECT Clinical Program by Year-End- CAMBRIDGE, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -
Read more →AKBAAkebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting
- Vadadustat Maintained Stable Hemoglobin Levels in All Three Dose Cohorts Following Conversion from rESA Therapy - - Vadadustat Demonstrated Sustained Improvements in Iron Mobilization - CAMBRIDGE, Mass., Nov. 7, 2015 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Read more →AKBAAkebia to Present at the Credit Suisse 24th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Jason A.
Read more →AKBAAkebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting
CAMBRIDGE, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data fro
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program Plan s to Ini
Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program Plans to Initiate Phase 3 PRO2TECT Clinical Program by Year-End Cambridge, Mass. October 6, 2015 Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovativ
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis
Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease -Treatment with Vadadustat Successfully Maintained Mean Hemoglobin Levels Following Conversion from rESA Therapy- -Vadadustat Demo
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Announces Second Quarter 2015 Financial Results -On Track to Release Top Line Data fr
Akebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Announces Second Quarter 2015 Financial Results -On Track to Release Top Line Data from Vadadustat Phase 2 Study in Dialysis Dependent Pa
Read more →AKBAAkebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease Study Meets Primary Endpoint Company Plans to Initiate Global Phase 3
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease Meets Primary Endpoint Company Plans to Initiate Global Phase 3 Registration Studies in 2015 Conference Call at 8:30 AM Easte
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com FOR IMMEDIATE RELEASE Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Dire
Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors Cambridge, Mass. September 15, 2014 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) bi
Read more →AKBAAkebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, Sept. 11, 2014 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patient
Read more →AKBAAkebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication | Akebia Therapeutics
Akebia Therapeutics has filed a lawsuit against CMS to challenge the rescinding of Medicare Part D coverage for Auryxia, an FDA-approved drug for iron deficiency anemia and hyperphosphatemia in chronic kidney disease patients. The company seeks to restore coverage and remove prior authorization requirements.
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Therapeutics Announces Expansion of Management Team Key additions will help drive str
Akebia Therapeutics Announces Expansion of Management Team Key additions will help drive strategic growth and advance lead clinical programs Cambridge, Mass. August 6, 2014 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential
Read more →AKBAAkebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142 T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of D
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors Cambridge, Mass. July 17, 2014 Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology
Read more →Competitive Position
How AKBA ranks across every disease it competes inCompetitive Position is a premium feature
See how AKBA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial